Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04227600 · ClinicalTrials.gov registry record · Phase 1
A Study of JR-171 in Patients With Mucopolysaccharidosis I
A Phase 1 study, sponsored by JCR Pharmaceuticals Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04227600 is a Phase 1 study that has completed, run by JCR Pharmaceuticals Co.. The registered enrollment target is 18 participants.
The verdict
NCT04227600, a Phase 1 study, has completed, sponsored by JCR Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of mucopolysaccharidosis type I (MPS I).
Interventions
- DRUG JR-171 (lepunafusp alfa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2022-08-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04227600
The ClinicalTrials.gov registry entry for NCT04227600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JCR Pharmaceuticals Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JR-171 (lepunafusp alfa) is the first listed.
NCT04227600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04227600 about?
NCT04227600 is a clinical study titled "A Study of JR-171 in Patients With Mucopolysaccharidosis I". Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of mucopolysaccharidosis type I (MPS I).
What is the current status of trial NCT04227600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-09-01. Estimated completion is 2022-08-02.
What interventions are being tested in trial NCT04227600?
The interventions under investigation include: JR-171 (lepunafusp alfa) (DRUG).
Who is sponsoring clinical trial NCT04227600?
This trial is sponsored by JCR Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.